A composition of entacapone comprising entacapone or pharmaceutically acceptable salts, PVPK30 and SDS is disclosed in the present invention, wherein the mass ratio of entacapone : PVPK30 : SDS is 1:0.05~0.6:0.06~0.1. The present invention also discloses preparative method and use of the composition of entacapone.

Provided herein in part is a method of treating a neurological or movement disorder in a patient in need thereof comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone or pharmaceutically acceptable salts thereof wherein said composition is administered substantially continuously and compositions that can be used in the disclosed methods.

Provided herein in part is a method of treating a neurological or movement disorder in a patient in need thereof comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone or pharmaceutically acceptable salts thereof wherein said composition is administered substantially continuously and compositions that can be used in the disclosed methods.

Provided herein in part is a method of treating a neurological or movement disorder in a patient in need thereof comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone or pharmaceutically acceptable salts thereof wherein said composition is administered substantially continuously and compositions that can be used in the disclosed methods.

The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapone levodopa and carbidopa or salts thereof along with one or more sugar alcohols wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone levodopa and carbidopa combination formulation marketed under the trade name Stalevo200

The present invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof along with one or more sugar alcohols; wherein the entacapone is co-micronized with one or more sugar alcohols. The invention also relates to processes of making such compositions.

A composition of entacapone comprising entacapone or pharmaceutically acceptable salts PVPK30 and SDS is disclosed in the present invention wherein the mass ratio of entacapone : PVPK30 : SDS is 1:0.05~0.6:0.06~0.1. The present invention also discloses preparative method and use of the composition of entacapone.